Physician

Stephen G Wallace, MD

According to 2025 Medicare claims, Stephen Wallace, MD (NPI: 1144255498) practices hematology/oncology in the Camden, NJ market, with the plurality of this provider's patient population coming from Burlington, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08057-3146.

Wallace's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 401 traditional Medicare patients, billed 67,706 HCPCS/CPT codes, and received $1,581,513 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 677 prescription claims across 136 beneficiaries totaling $2,741,151 in drug costs, led by Revlimid (Lenalidomide). 2016 DME data shows 17 claims. Open Payments data shows 3 records totaling $14. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $845,214 and ending at $1,581,513. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $884,329 to $2,741,151. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	327	48,611	$845,214
2016	423	65,481	$1,119,569
2017	429	78,257	$1,369,359
2018	379	78,480	$1,268,613
2019	343	95,380	$1,577,382
2020	307	91,600	$1,482,860
2021	328	106,966	$1,231,346
2022	381	60,444	$1,178,709
2023	377	57,492	$1,200,820
2024	401	67,706	$1,581,513

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	84	554	$884,329
2016	100	548	$687,732
2017	129	743	$1,392,910
2018	119	817	$1,854,106
2019	114	770	$1,673,483
2020	113	836	$1,820,147
2021	117	755	$2,550,953
2022	113	712	$2,646,128
2023	112	709	$2,591,213
2024	136	677	$2,741,151

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	110	$4,981
2016	N/R	17	$693
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	57	216	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	173	487	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	164	226	$70
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	103	319	$13
96372	Injection of drug or substance under skin or into muscle	51	83	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	24	672	$488,329
Xtandi	Enzalutamide	19	570	$271,574
Pomalyst	Pomalidomide	12	336	$262,743
Lonsurf	Trifluridine/Tipiracil Hcl	12	328	$234,003
Brukinsa	Zanubrutinib	11	330	$161,092

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$14	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$9,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Stephen G. Wallace, MD?

Tedicare shows public-source Medicare data for Stephen G. Wallace, MD (NPI 1144255498), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephen G. Wallace, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stephen G. Wallace, MD?

Stephen G. Wallace, MD is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Stephen G. Wallace, MD have Open Payments data?

Stephen G. Wallace, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.